Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04402489 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria
A Phase 3 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT04402489 is a Phase 3 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 184 participants.
The verdict
NCT04402489, a Phase 3 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP aged 12-75.
Interventions
- DRUG Placebo
- DRUG MT-7117 Low Dose
- DRUG MT-7117 High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2022-07-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04402489
The ClinicalTrials.gov registry entry for NCT04402489 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04402489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04402489 about?
NCT04402489 is a clinical study titled "Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria". The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP aged 12-75.
What is the current status of trial NCT04402489?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2020-06-01. Estimated completion is 2022-07-26.
What interventions are being tested in trial NCT04402489?
The interventions under investigation include: Placebo (DRUG), MT-7117 Low Dose (DRUG), MT-7117 High Dose (DRUG).
Who is sponsoring clinical trial NCT04402489?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.